SC-SENSOR-ELECTRONIC
Sensor Electronic Technology, Inc. (“SETi”), a leading global innovator of deep UV LED products and technology, announced that it successfully obtained a permanent injunction in a patent infringement lawsuit against Bolb, Inc. (“Bolb”), and Quantum Egg, Inc. (“Q-Egg”).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191205005031/en/
The California Northern District federal court issued a permanent injunction against the sales of an accused UV LED sterilizer device, as well as any mere colorable variations, according to the parties’ stipulation. The Court will therefore prohibit the sale of similar products if they prove to be mere colorable variations of the accused products.
The asserted patents in this litigation cover fundamental UV LED technology, encompassing UV LED sterilizer structures and drivers, chip fabrication, and epitaxial layer growth.
Bolb is a UV LED company co-founded by former SETi employees, and Q-Egg was the distributor of the accused UV LED sterilizer device.
The UV LED market has expanded to a range of fields, including air and water purification devices, as well as medical and bio devices for skin care. The UV LED market value will grow up to $1.2 billion in 2022 according to a market report from LEDinside (2018).
SETi has also collaborated with South Korean UV LED company Seoul Viosys Co., Ltd. (“SVC”), resulting in the development of Violeds technology for UV LED-based disinfection, deodorization, phototherapy and curing. Violeds technology has been used by the US National Aeronautics and Space Administration (NASA) aboard the International Space Station (ISS). SETi also supplies UV LED products to America’s largest heating and cooling manufacturing brand company. This product has been recognized by customers for its high performance in sterilizing various bacteria that live inside air conditioner equipment and preventing it from spreading inside a home or office during operation.
“It is difficult to survive on a long-term basis in the UV LED industry without a strong foundation in intellectual property and technology expertise, something that SETi and SVC have gained thanks to their extensive investment in research and development,” said Chae Hon Kim, CEO of SETi.
“SETi believes in furthering a market of fair competition and investment in intellectual property. We believe that this rewards research and development, allowing entrepreneurs and small businesses to have their hard work recognized in the marketplace. We also believe in the importance of green technology. As a UV LED pioneer developing commercialized UV LED for the first time in the word, we plan to make our products available at even more competitive pricing to encourage the distribution of our green technology products in the market, thereby contributing to a clean and healthy environment,” added Kim.
Semicon Light Co, Ltd., an investor of Bolb, did sales promotion for the accused UV LED and sterilizer device UV LEDs in Japan and other countries.
About SETi
Sensor Electronic Technology, inc. (SETi), a division of Seoul Semiconductor (KOSDAQ 046890) and Seoul Viosys, is the world’s leading supplier of deep UV LEDs (emission wavelengths shorter than 340nm), as well as a broad portfolio of UV-B, and UV-C LED products and application solutions. SETi UV LEDs are certified to AS9100D with ISO 9001:2015, and the company is committed to meeting and exceeding the needs of customers and stakeholders through the highest level of quality management. To learn more, visit http://www.s-et.com/en/ .
About Seoul Viosys
Seoul Viosys is the world’s first UV LED solution provider. Established in 2002 as a subsidiary of Seoul Semiconductor, the company developed EPI, FAB, and UV LEDs. In 2005, it produced UVC LEDs of 275nm, 310nm and 340nm for the first time in the world. In 2007, it achieved mass production of Deep UV LEDs for 255nm~340nm and has become the only company to produce UV LEDs of all wavelengths. Seoul Viosys has more than 6,000 patents related to UV LED technology. Its UV LED modules provide strong sterilization and disinfection (UVC), skin regeneration (UVB) and effective cultivation for horticulture. It is an eco-friendly and healthy product with no harmful chemicals unlike conventional mercury lamps. The key products have been applied to applications for water/air purification and sterilization are opening new application possibilities for horticulture, residential, commercial, water treatment facilities, health care, and even automobiles. To learn more, visit http://www.seoulviosys.com/en/ .
View source version on businesswire.com: https://www.businesswire.com/news/home/20191205005031/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sai Life Sciences Opens Dedicated Facility for Veterinary APIs in Bidar, India18.9.2025 18:22:00 CEST | Press release
Sai Life Sciences (BSE: 544306 | NSE: SAILIFE), an innovator-focused Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the opening of Unit VI, a dedicated facility for Veterinary Active Pharmaceutical Ingredient (API) production, in Bidar, India. Located alongside Unit IV, the company’s flagship API manufacturing site, Unit VI has been established exclusively for veterinary APIs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250918612071/en/ Sai Life Sciences’ Veterinary APIs Unit in Bidar, India. The new facility is designed to meet the highest standards of safety, sustainability, and regulatory compliance, ensuring the production of high-quality APIs for veterinary applications. With this expansion, Sai Life Sciences aims to provide efficient and scalable manufacturing solutions to leading global animal health companies. Making the announcement, Krishna Kanumuri, CEO & Managing Direct
Celltrion Announces Commercial Availability of Omlyclo™ Across Europe at EADV 202518.9.2025 17:45:00 CEST | Press release
Celltrion’s Omlyclo™, the first and only omalizumab biosimilar in Europe, will be commercially available starting in Norway, with subsequent rollouts in European countries Results from the global Phase III clinical trial of Omlyclo™ (CT-P39) for the treatment of chronic spontaneous urticaria (CSU), allergic asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) will be presented at a satellite symposium during the 2025 European Academy of Dermatology and Venereology (EADV) Congress Celltrion highlights the strength of its expanding dermatology portfolio with positive clinical results for CT-P55, a biosimilar candidate referencing secukinumab With the launch of Omlyclo™, Celltrion underscores its commitment to advancing innovative and accessible treatments in immunology and dermatology Celltrion, Inc. today showcased its longstanding commitment to expanding its biosimilar portfolio in the field of immuno-dermatology by attending the 2025 European Academy of Dermatology and Venereo
Andersen Consulting tilføjer samarbejdsfirmaet Charter18.9.2025 17:14:00 CEST | Pressemeddelelse
Andersen Consulting udvider sine digitale transformationskapaciteter gennem en samarbejdsaftale med Charter, et canadisk konsulentfirma, der er specialiseret i IT-strategi, managed services og applikationslevering. Charter blev grundlagt i 1997 og leverer teknologiprojekter med en forretningsorienteret tankegang og dyb teknisk ekspertise, herunder inden for IT-rådgivning, cloud-infrastruktur, cybersikkerhed, applikationsudvikling, projektlevering og forretningsarkitektur. Charter hjælper traditionelle virksomheder, offentlige institutioner, tjenesteudbydere og mellemstore kunder med implementering, netværksinfrastruktur og kundeorienterede applikationer – der leveres gennem en livscyklus-tilgang fra strategi til udførelse. "Vores mål hos Charter har altid været at fjerne kompleksiteten fra IT og hjælpe organisationer med at bevæge sig fremad med tillid," siger Kelly Michell, præsident for Charter. "Vores samarbejde med Andersen Consulting gør det muligt for os at bringe vores integrere
Andersen Consulting udvider sit udbud inden for cybersikkerhed og teknologi med tilføjelsen af Move18.9.2025 17:06:00 CEST | Pressemeddelelse
Andersen Consulting har indgået en samarbejdsaftale med Move, der er en førende virksomhed inden for it-infrastruktur, driftstjenester og digitale løsninger til virksomheder. Move befinder sig i Norge og Sverige. Move blev grundlagt i 1989 og leverer konsulentydelser, it-løsninger og driftstjenester. Virksomheden har ekspertise inden for cybersikkerhed, cloud-løsninger, server- og lagringsløsninger, netværkskommunikation og implementering af AI. Move samarbejder med mellemstore og store virksomheder om at designe, implementere og drive sikre, skalerbare og fremtidssikrede it-miljøer. "Dette samarbejde er en spændende mulighed for at skabe endnu større værdi for vores kunder," siger Roald Sannæs, der er administrerende direktør i Move. "Med vores kompetencer og Andersen Consultings globale rækkevidde og ekspertise kan vi levere mere helhedsorienterede løsninger, der hjælper organisationer med at løse nutidens udfordringer og forudse fremtidens muligheder." "Move har opbygget et godt ren
Setting the Standard: AMRA Medical Recognized as one of TIME Magazine’s ‘World’s Top HealthTech Companies’18.9.2025 16:40:00 CEST | Press release
The inaugural ranking by TIME, in partnership with Statista, features AMRA as one of the world’s leading health technology companies that are “driving innovation, enhancing accessibility, and contributing to a more effective and sustainable health care system” AMRA Medical is proud to share its inclusion in the World’s Top HealthTech Companies list, published today by TIME in collaboration with Statista. This recognition positions AMRA among an elite group of global innovators that are leading healthcare transformation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250918372780/en/ AMRA Medical Recognized as one of TIME Magazine’s ‘World’s Top HealthTech Companies’ The selection, which comes just one week after celebrating AMRA’s 15 years of progress and innovation within the body composition space, highlights AMRA’s long-standing commitment to becoming a global leader in health informatics. By delivering detailed, reproduc
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom